FINWIRES · TerminalLIVE
FINWIRES

Ajanta Pharma Gets Five Observations from US FDA After Paithan, India Unit Inspection

-- Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) has received five observations from the US FDA concluded an inspection at our manufacturing facility at Paithan in Maharashtra, India, according to a filing to the Indian stock exchanges.

The regulator inspected the facility from April 13 to 21 and closed with the issuance of Form-483 with five observations.

The company said it will respond to the U.S. FDA within the stipulated timeline.

The company's shares were down nearly 1% in recent trade.

相关文章